Interleukin-33 increases the sensitivity of multiple myeloma cells to the proteasome inhibitor bortezomib through reactive oxygen species-mediated inhibition of nuclear factor kappa-B signal and stemness properties

Abstract

The proteasome inhibitor bortezomib (BTZ) is the first-line therapy for multiple myeloma (MM). BTZ resistance largely limits its clinical application in MM. Interleukin-33 (IL-33) exerts antitumor effects through various mechanisms, including enhancing antitumor immunity and promoting the apoptosis of cancer cells. Here, the synergistic anti-MM effect of IL-33 and BTZ was verified, and the underlying mechanisms were elucidated. Bioinformatic analysis indicated that IL-33 expression levels were downregulated in MM, and that BTZ-treated MM patients with high IL-33 levels had better prognosis than those with low IL-33 levels. Moreover, the patients with high IL-33 levels had a better treatment response to BTZ. Further immune analysis suggested that IL-33 can enhance the anti-MM immunity. IL-33 and BTZ synergistically inhibited proliferation and induced apoptosis of MM cells, which was mediated by the excessive accumulation of cellular reactive oxygen species (ROS). Furthermore, increased ROS hindered the nuclear translocation of NF-κB-p65, thereby decreasing the transcription of target stemness-related genes (SOX2, MYC, and OCT3/4). These effects induced by the combination therapy could be reversed by eliminating ROS by N-acetylcysteine. In conclusion, our results indicated that IL-33 enhanced the sensitivity of MM to BTZ through ROS-mediated inhibition of nuclear factor kappa-B (NF-κB) signal and stemness properties.

Keywords

bortezomib / IL-33 / multiple myeloma / NF-κB / ROS / stemness

References

1	HT Wu, XY Zhao. Regulation of CD38 on multiple myeloma and NK cells by monoclonal antibodies. Int J Biol Sci. 2022;18(5):1974-1988.
2	K Beider, E Rosenberg, V Dimenshtein-Voevoda, et al. Blocking of transient receptor potential vanilloid 1 (TRPV1) promotes terminal mitophagy in multiple myeloma, disturbing calcium homeostasis and targeting ubiquitin pathway and bortezomib-induced unfolded protein response. J Hematol Oncol. 2020;13(1):158.
3	P Yang, Y Qu, M Wang, et al. Pathogenesis and treatment of multiple myeloma. MedComm. 2022;3(2):e146.
4	Q Wang, Z Lin, Z Wang, et al. RARgamma activation sensitizes human myeloma cells to carfilzomib treatment through the OAS-RNase L innate immune pathway. Blood. 2022;139(1):59-72.
5	Y Song, PMC Park, L Wu, et al. Development and preclinical validation of a novel covalent ubiquitin receptor Rpn13 degrader in multiple myeloma. Leukemia. 2019;33(11):2685-2694.
6	A Perrot. How I treat frontline transplantation-eligible multiple myeloma. Blood. 2022;139(19):2882-2888.
7	H Wang, Y Gong, L Liang, et al. Lycorine targets multiple myeloma stem cell-like cells by inhibition of Wnt/beta-catenin pathway. Br J Haematol. 2020;189(6):1151-1164.
8	H Yi, L Liang, H Wang, et al. Albendazole inhibits NF-kappaB signaling pathway to overcome tumor stemness and bortezomib resistance in multiple myeloma. Cancer Lett. 2021;520: 307-320.
9	L Ai, S Mu, C Sun, et al. Myeloid-derived suppressor cells endow stem-like qualities to multiple myeloma cells by inducing piRNA-823 expression and DNMT3B activation. Mol Cancer. 2019;18(1):88.
10	Y Yang, J Shi, Z Gu, et al. Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma. Cancer Res. 2015;75(3):594-604.
11	J Yang, Y Liao, B Wang, et al. EDARADD promotes colon cancer progression by suppressing E3 ligase Trim21-mediated ubiquitination and degradation of snail. Cancer Lett. 2023;577:216427.
12	MY Murray, L Zaitseva, MJ Auger, et al. Ibrutinib inhibits BTK-driven NF-kappaB p65 activity to overcome bortezomib-resistance in multiple myeloma. Cell Cycle. 2015;14(14):2367-2375.
13	Y Wang, H Qi, Y Liu, et al. The double-edged roles of ROS in cancer prevention and therapy. Theranostics. 2021;11(10):4839-4857.
14	Y Sun, Y Zheng, C Wang, Y Liu. Glutathione depletion induces ferroptosis, autophagy, and premature cell senescence in retinal pigment epithelial cells. Cell Death Dis. 2018;9(7):753.
15	B Niu, K Liao, Y Zhou, et al. Application of glutathione depletion in cancer therapy: enhanced ROS-based therapy, ferroptosis, and chemotherapy. Biomaterials. 2021;277:121110.
16	F Peng, M Liao, R Qin, et al. Regulated cell death (RCD) in cancer: key pathways and targeted therapies. Signal Transduct Target Ther. 2022;7(1):286.
17	BC Lipchick, EE Fink, MA Nikiforov. Oxidative stress and proteasome inhibitors in multiple myeloma. Pharmacol Res. 2016;105: 210-215.
18	L Monteleone, A Speciale, GE Valenti, et al. PKCalpha inhibition as a strategy to sensitize neuroblastoma stem cells to etoposide by stimulating ferroptosis. Antioxidants (Basel). 2021;10(5):691.
19	T Owari, N Tanaka, Y Nakai, et al. 5-Aminolevulinic acid overcomes hypoxia-induced radiation resistance by enhancing mitochondrial reactive oxygen species production in prostate cancer cells. Br J Cancer. 2022;127(2):350-363.
20	J Zhu, X Li, C Liang, et al. Apatinib suppresses lung cancer stem-like cells by complex interplay between beta-catenin signaling and mitochondrial ROS accumulation. Cell Death Discov. 2021;7(1):102.
21	MJ Morgan, ZG Liu. Crosstalk of reactive oxygen species and NF-kappaB signaling. Cell Res. 2011;21(1):103-115.
22	M Caillot, F Zylbersztejn, E Maitre, J Bourgeais, O Herault, B Sola. ROS overproduction sensitises myeloma cells to bortezomib-induced apoptosis and alleviates tumour microenvironment-mediated cell resistance. Cells. 2020;9(11):2357.
23	L Yin, T Kufe, D Avigan, D Kufe. Targeting MUC1-C is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated myeloma cell death. Blood. 2014;123(19):2997-3006.
24	M Fang, Y Li, K Huang, et al. IL33 promotes colon cancer cell stemness via JNK activation and macrophage recruitment. Cancer Res. 2017;77(10):2735-2745.
25	S Andreone, AR Gambardella, J Mancini, et al. Anti-tumorigenic activities of IL-33: a mechanistic insight. Front Immunol. 2020;11:571593.
26	X Chen, K Lu, NJ Timko, et al. IL-33 notably inhibits the growth of colon cancer cells. Oncol Lett. 2018;16(1):769-774.
27	Y Fang, L Zhao, H Xiao, et al. IL-33 acts as a foe to MIA PaCa-2 pancreatic cancer. Med Oncol. 2017;34(2):23.
28	C Yin, B Liu, Y Li, et al. IL-33/ST2 induces neutrophil-dependent reactive oxygen species production and mediates gout pain. Theranostics. 2020;10(26):12189-12203.
29	J Kellner, B Liu, Y Kang, Z Li. Fact or fiction—identifying the elusive multiple myeloma stem cell. J Hematol Oncol. 2013;6: 91.
30	S Yaccoby. Two states of myeloma stem cells. Clin Lymphoma Myeloma Leuk. 2018;18(1):38-43.
31	Z Li, H Wang, Y Wang, et al. Luteolin inhibits the TGF-beta signaling pathway to overcome bortezomib resistance in multiple myeloma. Cancer Lett. 2023;554:216019.
32	X Gao, X Wang, Q Yang, et al. Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells. J Immunol. 2015;194(1):438-445.
33	M Akimoto, JI Hayashi, S Nakae, H Saito, K Takenaga. Interleukin-33 enhances programmed oncosis of ST2L-positive low-metastatic cells in the tumour microenvironment of lung cancer. Cell Death Dis. 2016;7(1):e2057.
34	C Musolino, A Allegra, M Profita, et al. Reduced IL-33 plasma levels in multiple myeloma patients are associated with more advanced stage of disease. Br J Haematol. 2013;160(5):709-710.
35	GM Boukhaled, S Harding, DG Brooks. Opposing roles of type I interferons in cancer immunity. Annu Rev Pathol. 2021;16: 167-198.
36	H Ikeda, LJ Old, RD Schreiber. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev. 2002;13(2):95-109.
37	Y Jiang, X Li, F Qian, et al. Fine-tuning bacterial cyclic di-AMP production for durable antitumor effects through the activation of the STING pathway. Research (Wash D C). 2023;6: 0102.
38	C Hadjiaggelidou, E Katodritou. Regulatory T-cells and multiple myeloma: implications in tumor immune biology and treatment. J Clin Med. 2021;10(19):4588.
39	X Feng, L Zhang, C Acharya, et al. Targeting CD38 suppresses induction and function of T regulatory cells to mitigate immunosuppression in multiple myeloma. Clin Cancer Res. 2017;23(15):4290-4300.
40	K Giannopoulos, W Kaminska, I Hus, A Dmoszynska. The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myeloma. Br J Cancer. 2012;106(3):546-552.
41	B Salik, MJ Smyth, K Nakamura. Targeting immune checkpoints in hematological malignancies. J Hematol Oncol. 2020;13(1):111.
42	A Adhikary, S Mohanty, L Lahiry, DM Hossain, S Chakraborty, T Das. Theaflavins retard human breast cancer cell migration by inhibiting NF-kappaB via p53-ROS cross-talk. FEBS Lett. 2010;584(1):7-14.
43	HP Hougen. The athymic nude rat. Immunobiological characteristics with special reference to establishment of non-antigen-specific T-cell reactivity and induction of antigen-specific immunity. APMIS Suppl. 1991;21: 1-39.
44	CS Oakley, MA Welsch, YF Zhai, CC Chang, MN Gould, CW Welsch. Comparative abilities of athymic nude mice and severe combined immune deficient (SCID) mice to accept transplants of induced rat mammary carcinomas: enhanced transplantation efficiency of those rat mammary carcinomas that have elevated expression of neu oncogene. Int J Cancer. 1993;53(6):1002-1007.